Catalyst Pharmaceutical Partners Provides Updates On Progress of Phase 3 Firdapse Study In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
August 11, 2014 at 08:05 AM EDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative ...